帕金森病患者高剂量辅酶Q10的试点试验。

Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease.

作者信息

Shults Clifford W, Flint Beal M, Song David, Fontaine Deborah

机构信息

Department of Neurosciences, University of California, San Diego, La Jolla 92093-0662, USA.

出版信息

Exp Neurol. 2004 Aug;188(2):491-4. doi: 10.1016/j.expneurol.2004.05.003.

DOI:10.1016/j.expneurol.2004.05.003

PMID:15246848

Abstract

The safety and tolerability of high dosages of coenzyme Q10 were studied in 17 patients with Parkinson's disease (PD) in an open label study. The subjects received an escalating dosage of coenzyme Q10--1200, 1800, 2400, and 3000 mg/day with a stable dosage of vitamin E (alpha-tocopherol) 1200 IU/day. The plasma level of coenzyme Q10 was measured at each dosage. Thirteen of the subjects achieved the maximal dosage, and adverse events were typically considered to be unrelated to coenzyme Q10. The plasma level reached a plateau at the 2400 mg/day dosage and did not increase further at the 3000 mg/day dosage. Our data suggest that in future studies of coenzyme Q10 in PD, a dosage of 2400 mg/day (with vitamin E/alpha-tocopherol 1200 IU/day) is an appropriate highest dosage to be studied.

摘要

在一项开放标签研究中，对17例帕金森病（PD）患者进行了高剂量辅酶Q10安全性和耐受性的研究。受试者接受递增剂量的辅酶Q10——每天1200、1800、2400和3000毫克，同时每天服用稳定剂量的维生素E（α-生育酚）1200国际单位。在每个剂量下均测定辅酶Q10的血浆水平。13名受试者达到最大剂量，不良事件通常被认为与辅酶Q10无关。血浆水平在每天2400毫克剂量时达到平台期，在每天3000毫克剂量时未进一步升高。我们的数据表明，在未来关于辅酶Q10治疗帕金森病的研究中，每天2400毫克（同时服用维生素E/α-生育酚1200国际单位）是适合研究的最高剂量。